FDA Approves Niraparib and Abiraterone Acetate Plus Prednisone for BRCA2-mutated Metastatic Castration-Sensitive Prostate Cancer By Ogkologos - January 7, 2026 219 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the AMPLITUDE study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Life beyond cancer: Improving the long term side effects for children... September 22, 2022 How to Cope With Waiting Periods During Cancer: An Expert Perspective June 1, 2023 Five Fraction SBRT Noninferior to Moderately Fractionated Image-Guided Radiotherapy for Patients... November 7, 2024 Limited Efficacy of Nivolumab plus Ipilimumab in Adenoid Cystic Carcinomas, but... September 11, 2023 Load more HOT NEWS Neoadjuvant Followed by Adjuvant Pembrolizumab Prolongs Event-Free Survival Compared to Adjuvant... Efficacy and Safety of FOLFIRI With Durvalumab With or Without Tremelimumab... 11 Children Orphaned and Unable to Pay for Funeral After Their... Handmade Artisan Gifts For Under $30
